Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009

pical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future eve
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... is the device," Nobel laureate Herbert Kroemer famously ... found at the junctures where layers of different ... the interfaces between layers of metal oxides are ... favorites as spintronics, high-temperature superconductors, ferroelectrics and multiferroics. ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... by Buffalo BioBlower Technologies LLC ("B3") as the critical ... 2 award from the Army Corps of Engineers.  B3 ... kills all biological contaminants and destroys VOCs and other ...
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... to win races on the Formula 1 track could help ... between McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based ... funded by healthcare provider Simplyhealth. Telemetry technology, which ...
Breaking Biology Technology:A deeper look at interfaces 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4
... subsidiary of Milwaukee-based Merge Healthcare, said it will ... surgeons . , ,The company's OrthoWorks product will ... communications system (PACS), helping support joint arthroplasty, spine, ... the firm said. , ,Mayo Clinic has 70 ...
... Installation work on Milwaukee's Wi-Fi network could begin in ... and Midwest Fiber Networks said Thursday. , ,The ... which last month selected Midwest Fiber to build and maintain ... is dry on the agreements, "equipment will be mounted on ...
... Europe, I can't help making the obvious comparisons between ... countries. , ,I've written before about Wi-Fi. In the ... about anywhere, and there is relative good will about ... Wi-Fi is not public and not inexpensive. I'm sending ...
Cached Biology Technology:U.S. risks third-world status in key technology 2U.S. risks third-world status in key technology 3
(Date:4/23/2014)... conclusive evidence that the source of a unique rhythmic ... called the "bio-duck," is the Antarctic minke whale ( ... personnel in the 1960s who thought it sounded like ... various locations in the Southern Ocean, but its source ... 2013, an international team of researchers deployed acoustic tags ...
(Date:4/23/2014)... The shale gas boom has transformed the energy ... locations, it could cause conflict among the energy ... resources, say researchers. They add that degraded water ... adequate safeguards. The feature article appears in the ... , Meagan S. Mauter and colleagues point out ...
(Date:4/23/2014)... 23 April 2013 EMBO today announced Sophie Martin ... of the 2014 EMBO Gold Medal. The award acknowledges ... the organization and development of the cell. , Martin ... understand cellular polarity, in particular the way in which ... and cell division. In the last 11 years, she ...
Breaking Biology News(10 mins):Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3How to avoid water wars between 'fracking' industry and residents 2EMBO Gold Medal 2014 awarded to Sophie Martin 2
... of Leicester in collaboration with Northamptonshire Police is ... John Bond, from Northamptonshire Police Scientific Support Unit ... of Leicester,s Forensic Research Centre developed- in collaboration ... fingerprints, even after the print itself has been ...
... June 22 The Federal Bureau of Investigation (FBI) ... a five-year, $47 million contract to continue managing the ... Service (CSS) program. The contract covers the conversion of ... electronic records for the FBI. , , ...
... Delays in cargo screening significantly extend the time of ... foolproof and rapid screening and detection systems. At the ... need for efficient access control systems in ports and ... , , New analysis from Frost & Sullivan ...
Cached Biology News:New advance in revolutionary 'bullet fingerprinting' technique 2Federal Bureau of Investigation Awards Lockheed Martin Biometric Card Scanning Service Contract 2Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 2Growing Demand for Rapid Screening and Detection Systems Pushes the European Maritime Security Market, Finds Frost & Sullivan 3
... overlays are commonly used in ... "DNA grade" agaroses either contain ... insect cells or lack the ... good overlays. Novagen's BacPlaque Agarose ...
AgarPlaque Plus Agarose 50 grams...
...
...
Biology Products: